The tyrosine phosphatase Shp2 directs Neuregulin-1/ErbB signaling throughout Schwann cell developmentIn vivo analysis of Schwann cells associated with peripheral nerves in control and Wnt1-cre Shp2 fl/fl mice at the indicated developmental stagesusing (A,B) immunohistochemistry for BFABP (red) and neurofilament (NF, green), (C,D) in situ hybridization with a Sox10-specific probe, and (E,F)histological sections stained with hematoxylin and eosin. Note the reduced numbers of Schwann cells at Shp2 mutant peripheral nerves.In vitro analysis of the role of Shp2 during Schwann cell proliferation and migration. (G) Southern blot and (H) Western blot analyses after HTNcreinduced recombination in cultured Shp2 fl/fl Schwann cells. (I,J) Quantification of the Nrg1-induced proliferation and migration indicates strongreduction of both cellular responses in the absence of Shp2. Shown are the percentage of Schwann cells that incorporated BrdU, or the percentageof Schwann cells that migrated into the scratched area, using control and Shp2 ∆/∆ Schwann cells (HTN-cre-treated Shp2 fl/fl Schwann cells) in thepresence and absence of Nrg1. (K-L´) Migration of Schwann cells into a scratched area.sion and metastasis-free survival time of patients.BAMBI inhibits TGFβ signaling and increases migrationin colon cancer cells. In mice, overexpression of BAMBIcaused colon cancer cells to form tumors that metastasizedmore frequently to liver and lymph nodes thancontrol cancer cells. Thus BAMBI regulates colorectalcancer metastasis by connecting the Wnt/β-cateninand TGFβ signaling pathways. The metastatic expressionsignature we describe, along with BAMBI levels,may be used in prognosis in the future. Our data alsoshow that developmental signaling pathways act inhierarchies and cooperate in tumor cell migration, invasionand metastasis.Skin cancer stem cell maintenance is dependanton catenin signaling throughout Schwann celldevelopmentIlaria Malanchi, Deepika Kassen, Thomas Hussenet, JörgHuelsken (EPFL/ISREC Lausanne), Amparo Cano (CSIC-UAMMadrid) and Walter Birchmeier.Proper canonical Wnt signaling guides healthy developmentin many tissues, but defects play a role in tumors,as revealed by the analysis of loss- and gain-of functionmutations in β-catenin. The recently identified cancerstem cells and normal stem cells share many characteristics,like the capacity for self-renewal and differentiationand their dependence on a particular microenvi-84 Cancer <strong>Research</strong>
onment, the (cancer) stem cell niche. We have identifieda population of cancer stem cells in mouse epidermaltumors, i.e. early squamous cell carcinomas, whichare dependent on β-catenin and that are phenotypicallyand functionally similar to normal bulge skin stem cells.These cancer stem cells can be isolated by cell sortingbased on the presence of the stem cell marker CD34 andabsence of other markers. In normal mouse skin, CD34 +bulge stem cells account for approximately 1.8% of keratinocytes.However, cutaneous tumors, induced bychemical (DMBA/TPA) carcinogenesis or by expression ofthe Ras oncogene, contain a 9-fold increase of the CD34 +cell population. The tumorigenic capacity of the CD34 +cells was over 100-fold greater than that of unsortedcells, when these were transplanted into the back skin ofNOD/SCID mice. Secondary tumors that formed aftertransplantation resembled the parental tumors; theycontained a small population of CD34 + stem cells.Remarkably, the deletion of β-catenin in DMBA/TPA orRas-induced tumors using an inducible system thatallows conditional mutagenesis after the addition oftamoxifen (K14-cre ERT2 ; β-catenin flox ) resulted in completetumor regression. Thus, canonical Wnt signals arerequired for the maintenance of skin cancer stem cells,whereas in normal skin they instruct bulge stem cellstowards the hair cell fate.The tyrosine phosphatase Shp2 directsNeuregulin-1/ErbB signaling throughoutSchwann cell developmentKatja Grossmann, Hagen Wende, Florian Paul, Cyril Cheret,Alistair Garratt, Daniel Besser, Herbert Schulz, MatthiasSelbach, Walter Birchmeier and Carmen Birchmeier.The non-receptor tyrosine phosphatase Shp2 has beenimplicated in tyrosine kinase, chemokine and integrinreceptor signaling. We have produced a floxed allele ofthe Shp2 gene in mice in order to study the biologicalfunction of this tyrosine phosphatase. We showed thatconditional mutation of Shp2 in neural crest cells and inmyelinating Schwann cells resulted in deficits in glialdevelopment that are remarkably similar to thoseobserved in mice mutant for Neuregulin-1 (Nrg1) or theNrg1 receptors, ErbB2 and ErbB3. In cultured Shp2mutant Schwann cells, Nrg1-evoked cellular responseslike proliferation and migration were virtually abolished,and Nrg1-dependent intracellular signaling wasaltered. Pharmacological inhibition of Src family andMAP kinases mimicked all cellular and biochemicaleffects of the Shp2 mutation, implicating Src as a primaryShp2 target during Nrg1 signaling. Our phenotypicand biochemical analyses thus demonstrate thatShp2 is an essential component in the transduction ofNrg1/ErbB signals.Specific inhibitors of the protein tyrosinephosphatase Shp2 identified by high-throughputdockingKlaus Hellmuth, Ching Tung Lum, Martin Würtele, MartaRosario, Walter Birchmeier, Stefanie Grosskopf (FMP),Jörg Rademann (FMP) and Jens von Kries (FMP).The protein tyrosine phosphatase Shp2 is a positive regulatorof growth factor signaling. Gain-of-functionmutations in several types of leukemia define Shp2 as abona fide oncogene. We performed a high-throughputin silico screen for small-molecular-weight compoundsthat bind the catalytic site of Shp2. We have identifiedthe phenylhydrazonopyrazolone sulfonate PHPS1 as apotent and cell-permeable inhibitor, which is specificfor Shp2 over the closely related tyrosine phosphatasesShp1 and PTP1B. PHPS1 inhibits Shp2-dependent cellularevents such as hepatocyte growth factor/scatter factor(HGF/SF)-induced epithelial cell scattering and branchingmorphogenesis. PHPS1 also blocks Shp2-dependentdownstream signaling, namely HGF/SF-induced sustainedphosphorylation of the Erk1/2 MAP kinases anddephosphorylation of paxillin. Furthermore, PHPS1 efficientlyinhibits activation of Erk1/2 by the leukemiaassociatedShp2 mutant, Shp2-E76K, and blocks theanchorage-independent growth of a variety of humantumor cell lines. The PHPS compound class is thereforesuitable for further development of therapeutics for thetreatment of Shp2-dependent diseases.Selected PublicationsKlaus, A., and Birchmeier, W. (2008): Wnt signalling and its impact ondevelopment and cancer. Nature Rev. Cancer 8, 387-398Grigoryan, T., Wend, P., Klaus, A., and Birchmeier, W. (2008): Decipheringthe function of canonical Wnt signals in development and disease: conditionalloss- and gain-of-function mutations of beta-catenin in mice.Genes & Development 22, 2308-2341Malanchi, I., Peinado, H., Kassen, D., Hussenet, T., Metzger, D., Chambon,P., Huber, M., Hohl, D., Cano, A., Birchmeier, W., and Huelsken, J. (2008):Cutaneous cancer stem cell maintenance is dependent on beta-cateninsignalling. Nature 452, 650-654Hellmuth, K., Grosskopf, S., Tung Lum, C., Wuertele, M., Roeder, N., Kries v.,JP, Rosário, M., Rademann, J., and Birchmeier, W. (2008): Specific inhibitorsof the protein tyrosine phosphatase Shp2 identified by high-throughputdocking. Proc. Natl. Acad. Sci. USA. 105, 7275-7280Fritzmann, J., Morkel, M., Besser, D., Budczies, J., Kosel, F., Brembeck, F.H.,Stein, U., Fichtner, I., Schlag, P.M., and Birchmeier, W. (2009): A colorectalcancer expression profile that includes transforming growth factor betainhibitor BAMBI predicts metastatic potential. Gastroenterology 137,165-175Patent<strong>MDC</strong> 0501: Shp-2 inhibitors, pharmaceutical compositions comprisingthem and their use for treating phosphatase-mediated diseases.W. Birchmeier, K. Hellmuth. EP 05 090 160.2.Cancer <strong>Research</strong> 85
- Page 1:
Research Report 2010MAX DELBRÜCK C
- Page 4 and 5:
ContentInhaltContentInhalt.........
- Page 6 and 7:
Surgical OncologyPeter M. Schlag...
- Page 11 and 12:
at the MDC. The role of the institu
- Page 13 and 14:
in discovering genes that contribut
- Page 16 and 17:
The ECRC offers research space and
- Page 18 and 19:
etween disciplines such as biology,
- Page 20 and 21:
approaches from bioinformatics/syst
- Page 23 and 24:
von Humboldt Foundation (AvH). The
- Page 25:
organization to a larger, multi-fac
- Page 28 and 29:
Cardiovascular and Metabolic Diseas
- Page 30 and 31:
electrical signals. More recent wor
- Page 32 and 33:
Basic Cardiovascular FunctionStruct
- Page 34 and 35:
Figure 2: SORLA and sortilin in neu
- Page 36 and 37:
Annette Hammes(Delbrück Fellow)Str
- Page 38 and 39:
Ingo L. MoranoStructure of the Grou
- Page 40 and 41:
Figure 3. Membrane resealing assay
- Page 42 and 43:
Michael GotthardtStructure of the G
- Page 44 and 45:
Structure of the GroupSalim Seyfrie
- Page 46 and 47:
Structure of the GroupFerdinand le
- Page 48 and 49:
Francesca M. SpagnoliStructure of t
- Page 50 and 51:
Structure of the GroupKai M. Schmid
- Page 52 and 53:
Genetics and Pathophysiology of Car
- Page 54 and 55:
Figure 2. Planariato experimentally
- Page 56 and 57:
Norbert HübnerStructure of the Gro
- Page 58 and 59:
Structure of the GroupGroup LeaderF
- Page 60 and 61: Figure 2. Omega-3 fatty acids prote
- Page 62 and 63: Structure of the GroupDominik N. M
- Page 64 and 65: Rainer DietzStructure of the GroupG
- Page 66 and 67: Figure 2. Cardiac-restricted ablati
- Page 68 and 69: Ludwig ThierfelderStructure of the
- Page 70 and 71: standing of the molecular and cellu
- Page 72 and 73: Structure of the GroupThoralf Niend
- Page 74 and 75: Michael BaderStructure of the Group
- Page 76 and 77: Natriuretic peptide systemJens Butt
- Page 78 and 79: Structure of the GroupZsuzsanna Izs
- Page 80 and 81: Young-Ae LeeStructure of the GroupG
- Page 82 and 83: Structure of the GroupMatthias Selb
- Page 84 and 85: Matthew PoyStructure of the GroupGr
- Page 86 and 87: Jana WolfStructure of the GroupGrou
- Page 88 and 89: Structure of the GroupGroup LeaderD
- Page 91 and 92: Cancer Research ProgramKrebsforschu
- Page 93 and 94: are responsible for the emergence o
- Page 95 and 96: tral component of the canonical Wnt
- Page 97 and 98: lead to an aberrant constitutive ac
- Page 99 and 100: How Notch- and TGFβ signaling casc
- Page 101 and 102: tures of the chronic phase in human
- Page 103 and 104: oped a new safeguard that is based
- Page 105 and 106: Graduate StudentsSeda Cöl ArslanCa
- Page 107 and 108: investigation, as is the cause of c
- Page 109: Graduate StudentsÖzlem Akilli Özt
- Page 113 and 114: The pluripotent state of murine and
- Page 115 and 116: In the morula of the early mouse em
- Page 117 and 118: Graduate StudentsRami Hamscho*Qingb
- Page 119 and 120: esis and granulopoiesis. We showed
- Page 121 and 122: URE ∆/∆ mice regularly develope
- Page 123 and 124: PD Dr. Wolfgang Walther (GroupLeade
- Page 125 and 126: For the delivery of naked DNA into
- Page 127 and 128: ACBDMyc and FoxO transcription fact
- Page 129 and 130: Graduate StudentsKatrin BagolaHolge
- Page 131 and 132: Heinemann, we could also identify t
- Page 133 and 134: Above: Tip of chromosom3L showing t
- Page 135 and 136: Graduate StudentsSarbani Bhattachar
- Page 137 and 138: vesicle transport to the Golgi. Our
- Page 139 and 140: acbFigure 1a: EHD2 is tubulatingpho
- Page 141 and 142: KnowledgeProbabilitiesknownPossible
- Page 143 and 144: Graduate and undergraduatestudentsU
- Page 145 and 146: successive oncogenic mutations. We
- Page 147 and 148: CXCR5 drives the development of ect
- Page 149 and 150: Graduate and undergraduatestudentsW
- Page 151 and 152: Graduate andUndergraduate StudentsM
- Page 153 and 154: Angela MensenStefanie WittstockBjö
- Page 155 and 156: deficient mice, both major effector
- Page 157 and 158: ant of CD3 delta coding for a 45-me
- Page 159 and 160: Robert KudernatschLi-Min LiuAna Mil
- Page 161 and 162:
Sebastian GüntherTechnical Assista
- Page 163 and 164:
Graduate StudentsJana RolffAnnika W
- Page 165:
with murine hepatocytes showed morp
- Page 168 and 169:
Function and Dysfunction of the Ner
- Page 170 and 171:
The Neuroscience Department also es
- Page 172 and 173:
the coming years, Björn Schröder
- Page 174 and 175:
mice. Further analysis of the funct
- Page 176 and 177:
Signaling Pathways and Mechanisms i
- Page 178 and 179:
Control Olig3 -/-ABFigure 2. Geneti
- Page 180 and 181:
Thomas J. JentschStructure of the G
- Page 182 and 183:
Figure 2. Cellular model for ionic
- Page 184 and 185:
Structure of the GroupGroup LeaderF
- Page 186 and 187:
paired-pulse facilitation, less dep
- Page 188 and 189:
Gary R. LewinStructure of the Group
- Page 190 and 191:
Model summarizing the three waves o
- Page 192 and 193:
Structure of the GroupInes Ibañez-
- Page 194 and 195:
Jochen C. MeierStructure of the Gro
- Page 196 and 197:
Björn Christian SchroederStructure
- Page 198 and 199:
Structure of the GroupJan Siemens(S
- Page 200 and 201:
Structure of the GroupGroup LeaderD
- Page 202 and 203:
Imaging of the Living BrainStructur
- Page 204 and 205:
Pathophysiological Mechanisms of Ne
- Page 206 and 207:
Figure 2. Iba1 positive microglia c
- Page 208 and 209:
Erich E. WankerStructure of the Gro
- Page 210 and 211:
Scientific-Technical StaffAnja Frit
- Page 212 and 213:
Structure of the GroupJan Bieschke(
- Page 215 and 216:
Berlin Institute of Medical Systems
- Page 217 and 218:
etes, metabolic diseases and neurod
- Page 219 and 220:
A number of MDC investigators have
- Page 221 and 222:
Technical AssistantsClaudia Langnic
- Page 223 and 224:
has become a standardized data flow
- Page 225:
Phylogeny of cellulase genes from P
- Page 228 and 229:
Experimental and Clinical Research
- Page 230 and 231:
his patients, and a basic research
- Page 232 and 233:
The ultrahigh field MR facility was
- Page 234 and 235:
Structure of the GroupSimone Spuler
- Page 236 and 237:
Ralph KettritzStructure of the Grou
- Page 238 and 239:
Structure of the GroupJeanette Schu
- Page 240 and 241:
Maik GollaschStructure of the Group
- Page 243 and 244:
Technology PlatformsComputational B
- Page 245 and 246:
projects/ard/] to detect repeats li
- Page 247 and 248:
Simulation of line-scan images of C
- Page 249 and 250:
Development of an MRM method for qu
- Page 251 and 252:
mobility or turnover of the underly
- Page 253 and 254:
Left: Inside view of a FACSAria2 (f
- Page 255 and 256:
Examples fort the use of EM methods
- Page 257:
Oviducts lined up in pre-implantati
- Page 260 and 261:
Academic Appointments 2008-2009Beru
- Page 262 and 263:
Buch which is part of the Excellenc
- Page 264 and 265:
“Bioinformatics in Quantitative B
- Page 266 and 267:
Delbrück FellowsDelbrück-Stipendi
- Page 268 and 269:
Yinth Andrea Bernal-Sierra, a PhD s
- Page 270 and 271:
Congresses and Scientific MeetingsK
- Page 272 and 273:
SeminarsSeminare2008Speaker Institu
- Page 274 and 275:
Speaker Institute TitleKiyoshi Mori
- Page 276 and 277:
2009Speaker Institute TitleDavid G.
- Page 278 and 279:
Speaker Institute TitleJuri Rappsil
- Page 280 and 281:
The Helmholtz AssociationDie Helmho
- Page 282 and 283:
The Berlin-Buch CampusDer Campus Be
- Page 284:
the MDC, the existing collaboration
- Page 287 and 288:
Prof. Dr. Gary R. LewinMDC Berlin-B
- Page 289 and 290:
Prof. Dr. Renato ParoCenter of Bios
- Page 291 and 292:
Staff CouncilThe Staff Council is i
- Page 293 and 294:
Type of Financing/Art der Finanzier
- Page 295 and 296:
Research Projects 2008-2009Forschun
- Page 297 and 298:
CIC-5 Regulation und Endocytose am
- Page 299 and 300:
MDCMAX-DELBRÜCK-CENTRUMFÜR MOLEKU
- Page 301 and 302:
Index 275Bröske, A. . . . . . . .
- Page 303 and 304:
Index 277Gross, V. . . . . . . . .
- Page 305 and 306:
Index 279Kur, E. . . . . . . . . .
- Page 307 and 308:
Index 281Piano, F. . . . . . . . .
- Page 309 and 310:
Index 283Smink, J. . . . . . . . .
- Page 312 and 313:
Campus MapCampusplanRobert-Rössle-
- Page 314:
How to find your way to the MDCDer